360° Coverage : Discount Packages on Global Trends and Developments in Top...

Discount Packages on Global Trends and Developments in Top Therapeutic Classes

Apr 4 2014, 2:13am CDT | by

New York, NY, April 04, 2014 --(PR.com)-- The global biotechnology and pharmaceutical market have seen significant positive sentiments in the recent years, especially with innovation contributing to the availability of a range of new treatments for diseases. With the trend continuing, the markets expect innovation and improved drugs therapies through novel target discovery and technology platforms. The market optimism is based on the continuity in the flow of innovative products, implementation of strategic decisions to improve cost efficiency, strengthen therapeutic leadership, and hedge against generic threats. The pharmaceutical markets around the globe have seen significant developments in the treatment areas with innovation contributing to crucial developments in top therapeutic classes, which have considerably improved patients pain, function, and quality of life.

In keeping with the global demand, Research on Global Markets come up with a host of premium reports on the latest developments and trends across the globe on various new age drugs and treatment options that have evolved in the top therapeutic classes. Some of the latest reports are now available in discounted packages to assist healthcare companies across geographies take more informed decisions.

Combination Offer: 6 Reports on Developments in Top Therapeutic Classes
20% discount - You save: $2,500
Original Price: $12,500 | Offer price: $10,000

Treating Refractory Hematological Malignancies: Multiple Myeloma (MM) New Treatment Options Driving In-Licensing and M&A
The report offers a detailed financial and competitive analysis of the companies leading in this field for this indication - Celgene, Amgen (post-acquisition of Onyx pharma), and MorphoSys. Key M&A activities that have taken place in this area in the last 5 years and a list of products in early /late-stages of development available for in-licensing are highlighted in the report.

Newer Oral Anti Androgens – Expanding Role in the treatment Paradigm of Prostate Cancer
The report highlights the future role of Oral Antiandrogens in treatment of Prostate Cancer including how the approval and launch of various newer treatment options like Xtandi (Enzalutamide, Astellas/Medivation), Zytiga (Abiraterone acetate, JNJ), Jevtana (Cabazitaxel, Sanofi), & Xofigo (radium Ra 223, Boehringer Ingelheim) has evolved the treatment paradigm of treating late stage prostate cancer.

Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral drugs and Biologics to Change Future Treatment Paradigm
The report discusses novel Oral drugs and Biologics to change future treatment paradigm for Psoriasis - Plaque Psoriasis & Psoriatic Arthritis highlighting the unmet need in Psoriasis, alongwith a commercial outlook, current treatment options and treatment efficacy tools.

Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies
This comprehensive report on novel drug delivery system focuses mainly on the oral and injectable formulations of pharmaceuticals and specialty companies. Wherever possible, marketed drugs using a similar technology have been discussed as proof of validation along with the status of additional pipeline. The discussed proprietary formulation technologies includes Colal, Glide SDI, Arestat, GeoClock, GeoMatrix, FlashTab, Lock Tab, Medusa, Eligen, Oradur, EnteriCare and Saber.

Emergence Of Biogenerics Era In Japan: It's time to welcome antibody Biosimilars of Foreign Origins Soon
The report highlights the Investment Thesis in the space – with details of opening opportunities, Japanese companies and the Japan Biosimilar Pipeline- Expected Competition. The details of intensified competition in the Biosimilar space, alongwith the evolving landscape of the Biogenerics market in Japan with the country-specific drivers and hurdles are available in this report.

New Avatars of Microbes Super Bugs a Growing Threat Worldwide
The report provides details on the evolution and global dissemination of AMR, the unmet need in the critical setting esp. Gram Negative infections and CRE alongwith pipeline of novel targets being used to develop new drugs to treat infections and resistance. Pipeline of select drugs in mid and late clinical stage of development, alarming facts about AMR and the steps being taken by the regulatory authorities are focus points in this report. The report further discusses the role of diagnostics and preventive approach and the trends in pathogens and resistance in developing markets.

Contact Information:
Research on Global Markets
Gaurav Kumar
+91 22 4098 7690
Contact via Email
www.researchonglobalmarkets.com/

Read the full story here: http://www.pr.com/press-release/550859

Press Release Distributed by PR.com

 
 
 

<a href="/latest_stories/all/all/29" rel="author">PR.com</a>
PR.com press-releases.

 

blog comments powered by Disqus

Latest stories

NASDAQ is Back at 2000 Dot-Com Bubble Level
NASDAQ is Back at 2000 Dot-Com Bubble Level
The Dot-Com force is back at the NASDAQ. It took Silicon Valley 15 years to bring back the NASDAQ to the Dot-Com Bubble Levels. With startup valuations in the billions becoming the norm, Wall Street is following up with driving up the value of public traded tech companies.
 
 
Bill Gates Tops Forbes Billionaires List Again
Bill Gates Tops Forbes Billionaires List Again
Microsoft co-founder Bill Gates is back on top of the Forbes Billionaires list.
 
 
$75,000 Apple Watch revealed
$75,000 Apple Watch revealed
When Apple's designs are not exclusive enough then there are 3rd parties who add gold and diamonds to the iGadget to make them precious. Brikk announced the Lux Watch, a diamond studded version of the Apple Watch.
 
 
Sony will not Sell Off TV And Mobile Spinoffs
Sony will not Sell Off TV And Mobile Spinoffs
Sony President Kazuo Hirai clarified on Wednesday that the company will not immediately sell off the spun out TV and mobile phone business.